Reviva Pharmaceuticals Holdings Inc.

12/16/2024 | Press release | Distributed by Public on 12/16/2024 07:04

Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia[...]